Neoadjuvant durvalumab improves survival in early triple-negative breast cancer independent of pathological complete response

Article Medicine, General & Internal

Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer

P. Schmid et al.

Summary: The addition of pembrolizumab to neoadjuvant chemotherapy followed by adjuvant pembrolizumab after surgery significantly prolonged event-free survival in patients with early triple-negative breast cancer.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

Add to Collection

Review Oncology

The journey of tumor-infiltrating lymphocytes as a biomarker in breast cancer: clinical utility in an era of checkpoint inhibition

S. Loi et al.

Summary: The method described in 2014 allows quantification of tumor-infiltrating lymphocytes in breast cancer samples, showing strong prognostic value and potential for use in chemotherapy de-escalation studies. The inclusion of TIL biomarker in international guidelines and its association with better prognoses in TNBC and HER2+ BC have been confirmed. The recent focus has shifted to investigating the clinical utility of TIL in the setting of immune checkpoint-targeted agents, with TIL quantity potentially helping to identify patients who benefit most from PD-1/PD-L1 inhibition.

ANNALS OF ONCOLOGY (2021)

Add to Collection

Article Biochemistry & Molecular Biology

Durvalumab compared to maintenance chemotherapy in metastatic breast cancer: the randomized phase II SAFIR02-BREAST IMMUNO trial

Thomas Bachelot et al.

Summary: The study found that single-agent antibodies against PD-L1 as maintenance therapy did not significantly benefit the overall population with metastatic breast cancer, but showed improved overall survival in patients with triple-negative breast cancer. Durvalumab may have better sensitivity in patients with CD274 amplification. Analysis of lymphocyte infiltration and homologous recombination deficiency did not predict sensitivity to durvalumab, warranting further research. Maintenance chemotherapy was more effective than durvalumab in patients with hormone receptor-positive and Her2-negative disease.

NATURE MEDICINE (2021)

Add to Collection

Article Oncology

Immune-related Gene Expression Predicts Response to Neoadjuvant Chemotherapy but not Additional Benefit from PD-L1 Inhibition in Women with Early Triple-negative Breast Cancer

Bruno Sinn et al.

Summary: The study identified two specific gene signatures that could predict patient response to neoadjuvant PD-L1 inhibition in early triple-negative breast cancer, while CYT metric and proliferation-associated gene signatures were associated with treatment response in different arms. Higher expression of PD-L1 mRNA was found to be a general predictor of neoadjuvant therapy response, and genes related to antigen presentation and IFN signaling were suggested as potential candidates for further evaluation.

CLINICAL CANCER RESEARCH (2021)

Add to Collection

Article Oncology

First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis

L. A. Emens et al.

Summary: The study showed that although A + nP for first-line treatment of triple-negative breast cancer did not significantly improve overall survival in the overall population, clinically meaningful benefits were observed in patients with PD-L1 expression on tumor infiltrating immune cells. The combination therapy remained safe and tolerable with longer follow-up.

ANNALS OF ONCOLOGY (2021)

Add to Collection

Meeting Abstract Oncology